These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33369238)

  • 1. The effect of freezing and thawing of samples for anti-factor Xa testing for the determination of enoxaparin activity.
    Louw S; Gounden R; Vaughan J; Ntabeni L; Mayne A; Mayne ES
    Int J Lab Hematol; 2021 Jun; 43(3):e138-e140. PubMed ID: 33369238
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
    Brophy DF; Martin EJ; Gehr TW; Carr ME
    Am J Kidney Dis; 2004 Aug; 44(2):270-7. PubMed ID: 15264185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged anti-Xa activity due to enoxaparin at the end of pregnancy.
    Ortigueira M; Capanna F; Boehlen F; Martinez de Tejada B; Savoldelli G
    Anaesth Intensive Care; 2014 Sep; 42(5):668-70. PubMed ID: 25233184
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J; Picard-Willems B; Harder S
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Evaluation of a Factor Xa-Based Clotting Time Test for Enoxaparin: A Proof-of-Concept Study.
    Ng DPJ; Duffull SB; Faed JM; Isbister GK; Gulati A
    Clin Appl Thromb Hemost; 2018 May; 24(4):669-676. PubMed ID: 28731370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of freezing- and thawing-induced biological, chemical, and physical changes to enoxaparin solution.
    Patel RP; Narkowicz C; Jacobson GA
    J Pharm Sci; 2009 Mar; 98(3):1118-28. PubMed ID: 18661541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Plasmapheresis on the Anti-Factor Xa Activity of Enoxaparin in an Obese Adolescent Patient.
    Rahawi KW; Higgins KL; Noda C; Stultz JS
    Pharmacotherapy; 2017 Apr; 37(4):e16-e20. PubMed ID: 28152224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
    Olah Z; Szarvas M; Bereczky Z; Kerenyi A; Kappelmayer J; Boda Z
    Arch Pathol Lab Med; 2013 Jul; 137(7):967-73. PubMed ID: 23808469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the anti-factor Xa assay for the potency assessment of enoxaparin in pharmaceutical formulations.
    Dalmora SL; Júnior LB; Schmidt CA; Vaccari SF; Oliveira PR; Codevilla CF
    J AOAC Int; 2004; 87(6):1305-8. PubMed ID: 15675440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.
    Antonijoan RM; Rico S; Martínez-González J; Borrell M; Valcarcel D; Fontcuberta J; Barbanoj MJ
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):726-32. PubMed ID: 19954711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Strandberg K
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512144
    [No Abstract]   [Full Text] [Related]  

  • 13. Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma.
    Al-Sallami HS; Medlicott NJ
    J Pharm Pharmacol; 2015 Feb; 67(2):209-14. PubMed ID: 25557692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Assessment of Factor Xa Activity and Global Blood Coagulability Utilizing Novel Dielectric Coagulometry.
    Hamada S; Hasegawa Y; Oono A; Suzuki A; Takahashi N; Nishimura T; Koyama T; Hagihara M; Tohda S; Furukawa T; Hirao K; Sasano T
    Sci Rep; 2018 Oct; 8(1):16129. PubMed ID: 30382162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients.
    Helviz Y; Dzigivker I; Raveh-Brawer D; Hersch M; Zevin S; Einav S
    Isr Med Assoc J; 2016 Feb; 18(2):108-13. PubMed ID: 26979004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
    Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
    Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
    Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
    Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
    Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
    Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
    Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
    Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.